Grail Inc
NASDAQ:GRAL

Watchlist Manager
Grail Inc Logo
Grail Inc
NASDAQ:GRAL
Watchlist
Price: 99.8 USD
Market Cap: 3.9B USD

Grail Inc
Interest Income Expense

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Grail Inc
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Grail Inc
NASDAQ:GRAL
Interest Income Expense
$26.7m
CAGR 3-Years
332%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Interest Income Expense
-$2.6B
CAGR 3-Years
-5%
CAGR 5-Years
-4%
CAGR 10-Years
-7%
Gilead Sciences Inc
NASDAQ:GILD
Interest Income Expense
-$694m
CAGR 3-Years
22%
CAGR 5-Years
9%
CAGR 10-Years
-2%
Amgen Inc
NASDAQ:AMGN
Interest Income Expense
-$2.9B
CAGR 3-Years
-30%
CAGR 5-Years
-25%
CAGR 10-Years
-18%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Interest Income Expense
$476.3m
CAGR 3-Years
N/A
CAGR 5-Years
32%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Interest Income Expense
$1.4B
CAGR 3-Years
N/A
CAGR 5-Years
40%
CAGR 10-Years
N/A
No Stocks Found

Grail Inc
Glance View

Market Cap
3.6B USD
Industry
Biotechnology

Grail Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Menlo Park, California and currently employs 1,370 full-time employees. The company went IPO on 2024-06-12. GRAIL, Inc., formerly GRAIL, LLC, is a healthcare company, which is engaged in saving lives and shifting the paradigm in early cancer detection. The company is focused on alleviating the global burden of cancer by using next-generation sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its products include Galleri and Beyond. The Galleri test is a commercially available screening test for early detection of multiple types of cancer, which is termed multi-cancer early detection (MCED). Galleri screening test results can help guide next steps for a diagnosis of cancer by healthcare providers.

GRAL Intrinsic Value
26.42 USD
Overvaluation 74%
Intrinsic Value
Price

See Also

What is Grail Inc's Interest Income Expense?
Interest Income Expense
26.7m USD

Based on the financial report for Dec 31, 2024, Grail Inc's Interest Income Expense amounts to 26.7m USD.

What is Grail Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 3Y
332%

Over the last year, the Interest Income Expense growth was 236%. The average annual Interest Income Expense growth rates for Grail Inc have been 332% over the past three years .

Back to Top